Our main results were as follows: (1) SGLT2 inhibitors reduced hospitalizations for HF; (2) this reduction in hospitalizations for HF with SGLT2 inhibitors was observed regardless of the timing of the MI; (3) HF hospitalization rates did not differ significantly between patients with and without T2DM when SGLT2 inhibitors were used; (4) SGLT2 inhibitors were associated with a lower incidence of MACE; and (5) there was no significant difference in the incidence of MI, CV death, or all-cause mortality between patients treated with SGLT2 inhibitors versus placebo. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.